FTC second request extends review period for MiMedx and Sanara merger
MiMedx and Sanara MedTech both disclosed that the FTC issued a second request on October 15, 2026, extending the HSR waiting period for their merger.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
MiMedx Group has received a request for more information and documents from the US Federal Trade Commission, tied to its planned merger with Sanara MedTech. The agency sent the request on October 15, 2026. Under the HSR process, the waiting period now runs until 30 days after the company substantially complies with the request, unless it ends sooner.
According to a filing summary published by TradingView, MiMedx says it keeps cooperating with regulators and flags uncertainty about timing and expected benefits. Closing still depends on the HSR waiting period ending and on other closing conditions being met or waived. Sanara MedTech disclosed similar information.
why it matters
For investors, the timeline for closing the deal becomes less certain, which matters for shareholders of both companies. The event is routine for the broader market, but an extended antitrust review typically adds time before a deal can close, so deal watchers will track its progress.
tags
instruments
sources
- MiMedx Group receives FTC second request, extending HSR waiting period for Sanara merger — ru.tradingview.com, 16 October 2026 at 13:03 UTC
- Sanara MedTech receives FTC Second Request, HSR waiting period extended for MiMedx merger — ru.tradingview.com, 16 October 2026 at 13:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗